Business
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
DIJON, France, July 31, 2025--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2025, as approved by the Board of Directors on July 31, 2025.
About this update from Oncodesign Precision Medicine S.a.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/bd2759f74d421650715c378e02700aae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g7N7epiCUPksFprr.xMLVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bd2759f74d421650715c378e02700aae","width":480,"height":320}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The REVERT Phase 1b/2a clinical trial evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 has been submitted to the Swiss regulatory (Swissmedic) and ethics (Swiss ethics) authorities","length":207,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"OPM has reintegrated, in close collaboration with Servier, all data and product stocks for OPM-201","length":98,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Appointment of Christophe THURIEAU, Chief Research Officer at Servier, as an independent director","length":97,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Establishment of a maximum €5 million equity financing line with IRIS","length":69,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cost reduction plan rolled out in the first half of 2025","length":56,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"OPM's half-year net income thus stands at €9.8 million, due to the integration of OPM-201 inventories valued at €13 million by an external expert","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash position of €2.5 million as of June 30, 2025, reinforced in July 2025 by the receipt of €1.1 million in research tax credits","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"€1.7 million in R&D investments in our programs, mainly in the clinical development of OPM-101","length":98,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":903,"olType":false},{"type":"text","content":"DIJON, France, July 31, 2025--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precisio...